Fecal transplant for triple negative breast cancer guided by ctDNA

This study tests if giving patients a stool transplant (also called FMT) in capsules along with their first chemotherapy can help treat advanced pancreatic cancer that cannot be removed by surgery.

This trial tests whether fecal transplants (putting healthy donor bacteria into your gut) can help with side effects like diarrhea, constipation, or nausea caused by cancer treatments. It is for people with advanced gastrointestinal cancer who are about to start their fourth round of chemo or targeted therapy.

This trial tests whether a treatment that targets your gut bacteria (microbiome) can help fight triple-negative breast cancer before surgery. It is for people with newly diagnosed, untreated triple-negative breast cancer that has not spread far.

This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.

This trial tests whether a fecal microbiota transplant (FMT) can help overcome drug resistance in people with advanced liver cancer whose disease has worsened after a specific triple therapy (TACE, lenvatinib, and sintilimab). FMT involves transferring gut bacteria from a healthy donor to restore the balance of your gut microbiome, which may make your cancer more responsive to treatment again.

This trial tests whether a fecal transplant (a stool donation from a healthy person) can help patients with advanced stomach cancer respond better to treatment. If you qualify, you would receive the transplant through a colonoscopy, possibly along with other standard therapies.